Literature DB >> 19219392

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.

Henrik ten Freyhaus1, Daniel Dumitrescu, Henning Bovenschulte, Erland Erdmann, Stephan Rosenkranz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19219392     DOI： 10.1007/s00392-009-0752-3

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  10 in total

1.  Imatinib for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Werner Seeger; Friedrich Grimminger
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Long term imatinib treatment in pulmonary arterial hypertension.

Authors:  R Souza; O Sitbon; F Parent; G Simonneau; M Humbert
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

3.  Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

Authors:  Karen C Patterson; Ariel Weissmann; Tahamtan Ahmadi; Harrison W Farber
Journal:  Ann Intern Med       Date:  2006-07-18       Impact factor: 25.391

4.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

Authors:  Silvia Svegliati Baroni; Mariarosaria Santillo; Federica Bevilacqua; Michele Luchetti; Tatiana Spadoni; Matteo Mancini; Paolo Fraticelli; Paola Sambo; Ada Funaro; Andrius Kazlauskas; Enrico V Avvedimento; Armando Gabrielli
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

5.  [Diagnosis and therapy of chronic pulmonary hypertension].

Authors:  Horst Olschewski; M M Hoeper; M M Borst; R Ewert; E Grünig; F-X Kleber; B Kopp; C Opitz; F Reichenberger; A Schmeisser; D Schranz; I Schulze-Neick; H Wilkens; J Winkler; H Worth
Journal:  Clin Res Cardiol       Date:  2007-05       Impact factor: 5.460

6.  Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.

Authors:  M J Overbeek; J-W Lankhaar; N Westerhof; A E Voskuyl; A Boonstra; J G F Bronzwaer; K M J Marques; E F Smit; B A C Dijkmans; A Vonk-Noordegraaf
Journal:  Eur Respir J       Date:  2008-01-23       Impact factor: 16.671

7.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

8.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

Review 9.  Pulmonary hypertension: current diagnosis and treatment.

Authors:  Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2007-06-04       Impact factor: 5.460

10.  Congestive heart failure is a rare event in patients receiving imatinib therapy.

Authors:  Ehab Atallah; Jean-Bernard Durand; Hagop Kantarjian; Jorge Cortes
Journal:  Blood       Date:  2007-04-20       Impact factor: 22.113
  10 in total
  19 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 3.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 4.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

5.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

Review 6.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 7.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

8.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

Review 9.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

10.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.